{"id":"NCT02322788","sponsor":"AstraZeneca","briefTitle":"Comparing the Efficacy of Bricanyl M2 and Bricanyl M3 at 0.5 and 1.5 mg Dose Levels, to Allow for a Switch From Bricanyl Turbuhaler M2 to Bricanyl Turbuhaler M3","officialTitle":"A Randomised, Double-blind, Double-dummy, Multi-site, Phase III, Single Dose, 4-way Cross-over Pharmacodynamic Study Evaluating the Efficacy of Bricanyl Turbuhaler M3 Compared to Bricanyl Turbuhaler M2 by Studying the Protective Effect on Methacholine Induced Bronchoconstriction in Patients With Stable, Mild to Moderate Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-03","primaryCompletion":"2015-11","completion":"2015-11","firstPosted":"2014-12-23","resultsPosted":"2016-11-07","lastUpdate":"2017-01-13"},"enrollment":95,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"TRIPLE","primaryPurpose":"BASIC_SCIENCE"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Terbutaline sulphate","otherNames":["Terbutaline sulphate powder for inhalation, 0.5 mg (metered dose) terbutaline per inhalation"]},{"type":"DRUG","name":"Terbutaline sulphate","otherNames":["Terbutaline sulphate powder for inhalation, 0.4 mg (delivered dose) terbutaline per inhalation"]},{"type":"DRUG","name":"Placebo for terbutaline sulphate","otherNames":["Placebo powder for inhalation"]},{"type":"DRUG","name":"Placebo for terbutaline sulphate","otherNames":["Placebo powder for inhalation"]}],"arms":[{"label":"Bricanyl Turbuhaler M2, Active","type":"ACTIVE_COMPARATOR"},{"label":"Bricanyl Turbuhaler M3, Active","type":"ACTIVE_COMPARATOR"},{"label":"Turbuhaler M2, Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Turbuhaler M3, Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A randomised, double-blind, double-dummy, multi-site, phase III, single dose, 4-way cross-over pharmacodynamic study evaluating the efficacy of Bricanyl Turbuhaler M3 compared to Bricanyl Turbuhaler M2 by studying the protective effect on methacholine induced bronchoconstriction in patients with stable, mild to moderate asthma","primaryOutcome":{"measure":"Provocative Concentration of Methacholine Which Produces a 20% Fall in FEV1 (PC20)","timeFrame":"4 cross-over treatments (<1 day each) with 2-10 days between treatment washout periods","effectByArm":[{"arm":"M3 1.5 mg","deltaMin":17.7,"sd":null},{"arm":"M3 0.5 mg","deltaMin":9.88,"sd":null},{"arm":"M2 1.5 mg","deltaMin":20.1,"sd":null},{"arm":"M2 0.5 mg","deltaMin":10.78,"sd":null}],"pValues":[{"comp":"OG002 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG001","p":"<0.001"},{"comp":"OG001 vs OG003","p":null},{"comp":"OG000 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":4,"countries":["Canada","Netherlands","Sweden"]},"refs":{"pmids":["28232118"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":60},"commonTop":["Dysgeusia","Tremor","Palpitations","Nasopharyngitis","Headache"]}}